Advertisement

Drugs

, Volume 78, Issue 10, pp 983–994 | Cite as

Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management

  • Adena Zadourian
  • Taylor A. Doherty
  • Iwona Swiatkiewicz
  • Pam R. Taub
Therapy in Practice

Abstract

Postural orthostatic tachycardia syndrome (POTS) is a debilitating disease that predominantly affects young women. It is a multifactorial disorder that is characterized by severe tachycardia and orthostatic intolerance. Patients with POTS experience a variety of cardiac, neurological, and immunological symptoms that significantly reduce quality of life. In this review, a comprehensive framework is provided to aid in helping identify and treat patients with POTS. Given its heterogenous nature, it is crucial to understand each component of POTS in relation to one another instead of distinct parts. The framework highlights the overlap among the five main subtypes of POTS based on its pathophysiology (neuropathic, hypovolemic, primary hyperadrenergic, joint-hypermobility-related, and immune-related). Emphasis is placed on incorporating a multidisciplinary approach when treating patients with POTS, especially with a new focus towards immunotherapy. Although research has advanced our knowledge of POTS, there is still a critically unmet need to further our understanding and provide patients with the relief they need.

Notes

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this article.

Conflict of interest

Pam R. Taub has disclosed a potential conflict of interest as she has received a grant from Amgen to investigate the effect of Ivabradine in patients with POTS. Adena Zadourian, Taylor A. Doherty, and Iwona Swiatkiewicz have no conflicts of interest to disclose. This manuscript was prepared in Compliance with Ethical Standards.

References

  1. 1.
    Sheldon RS, Grubb BP, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41–63.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auto Res. 2011;21(2):69–72.CrossRefGoogle Scholar
  3. 3.
    Raj SR. The Postural Tachycardia Syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 2006;6:84–99.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15(9):60.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Raj SR. Postural Tachycardia Syndrome (POTS). Circulation. 2013;127(23):2336–42.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Grubb BP. Postural tachycardia syndrome. Circulation. 2008;117:2814–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Costa F, Sulur P, Angel M, et al. Intravascular source of adenosine during forearm ischemia in humans: implications for reactive hyperemia. Hypertension. 1999;33(6):1453–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Medow MS, Stewart JM. The postural tachycardia syndrome. Cardiol Rev. 2007;15(2):67–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Rosen SG, Cryer PE. Postural tachycardia syndrome. Reversal of sympathetic hyperresponsiveness and clinical improvement during sodium loading. Am J Med. 1982;72:847–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993;43:132–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Mathias CJ, Low DA, Iodice V, Owens AP, Kirbis M, Grahame R. Postural tachycardia syndrome—current experience and concepts. Nat Rev Neurol. 2011;8:22–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Wooley CF. Where are the diseases of yesteryear? DaCosta’s syndrome, soldiers heart, the effort syndrome, neurocirculatory asthenia–and the mitral valve prolapse syndrome. Circulation. 1976;53:749–51.CrossRefPubMedGoogle Scholar
  13. 13.
    Miller JW, Streeten DH. Vascular responsiveness to norepinephrine in sympathicotonic orthostatic intolerance. J Lab Clin Med. 1990;115:549–58.PubMedGoogle Scholar
  14. 14.
    Wieling W, Shepherd JT. Initial and delayed circulatory responses to orthostatic stress in normal humans and in subjects with orthostatic intolerance. Int Angiol. 1992;11:69–82.PubMedGoogle Scholar
  15. 15.
    Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci. 1999;317:75.CrossRefPubMedGoogle Scholar
  16. 16.
    Low PA, Opfer-Gehrking TL, Textor SC, et al. Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure. J Auton Nerv Syst. 1994;50:181.CrossRefPubMedGoogle Scholar
  17. 17.
    Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci. 1999;317:88.CrossRefPubMedGoogle Scholar
  18. 18.
    White AA, Doherty TA. Mast cell disorders and postural tachycardia syndrome. Auton Neurosci. (In press).Google Scholar
  19. 19.
    Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc. 2007;82:308.CrossRefPubMedGoogle Scholar
  20. 20.
    Kimpinski K, Figueroa JJ, Singer W, et al. A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 2012;87:746.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Garland EM, Raj SR, Black BK, Harris PA, Robertson D. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology. 2007;69:790–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Boris JR, Bernadzikowski T. Demographics of a large paediatric postural orthostatic tachycardia syndrome program. Cardiol Young. 2018;28:668–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Bhatia R, Kizilbash SJ, Ahrens SP, et al. Long-term outcomes of adolescent-onset postural orthostatic tachycardia syndrome. J Pediatr. 2016;173:149–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Moon J, Kim DY, Byun JI, et al. Orthostatic intolerance symptoms are associated with depression and diminished quality of life in patients with postural tachycardia syndrome. Health Qual Life Outcomes. 2016;14(1):144.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wells R, Spurrier AJ, Linz D, et al. Postural tachycardia syndrome: current perspectives. Vasc Health Risk Manag. 2018;14:1–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Fu Q, Vangundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2010;55:2858–68.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Raj SR, BiaggioniI YamhurePC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005;111:1574–82.CrossRefPubMedGoogle Scholar
  28. 28.
    Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000;343:1008–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Peltier AC, Garland E, Raj SR, et al. Distal sudomotor findings in postural tachycardia syndrome. Clin Auton Res. 2010;20:93–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Singer W, Spies JM, McArthur J, et al. Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies. Neurology. 2004;62:612–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Fouad FM, Tadena-Thome L, Bravo EL, Tarazi RC. Idiopathic hypovolemia. Ann Intern Med. 1986;104:298–303.CrossRefPubMedGoogle Scholar
  32. 32.
    Furlan R, Jacob G, Snell M, et al. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation. 1998;98:2154–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000;342:541–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Lambert E, Eikelis N, Esler M, et al. Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 2008;1:103–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Khan AW, Ziemann M, Corcoran SJ. NET silencing by let-7i in postural tachycardia syndrome. JCI Insight. 2017;2(6):e90183.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wallman D, Weinberg J, Hohler AD. Ehlers-Danlos Syndrome and Postural Tachycardia Syndrome: a relationship study. J Neurol Sci. 2014;340(1–2):99–102.CrossRefPubMedGoogle Scholar
  37. 37.
    Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P. Cardiovascular autonomic dysfunction in Ehlers-Danlos syndrome—Hypermobile type. Am J Med Genet Part C Semin Med Genet. 2017;175(1):168–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med. 2003;115:33–40.CrossRefPubMedGoogle Scholar
  39. 39.
    Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Comparative clinical profile of postural orthostatic tachycardia patients with and without joint hypermobility syndrome. Indian Pacing Electrophysiol J. 2010;10:173–8.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr. 1999;135:494–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Grigoriou E, Boris JR, Dormans JP. Postural orthostatic tachycardia syndrome (POTS): association with Ehlers-Danlos syndrome and orthopaedic considerations. Clin Orthop Relat Res. 2015;473(2):722–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Shibao C, Arzubiaga C, Roberts LJ, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385–90.CrossRefPubMedGoogle Scholar
  43. 43.
    Li H, Yu X, Liles C, et al. Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc. 2014;3(1):e000755.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000;343(12):847–55.CrossRefPubMedGoogle Scholar
  45. 45.
    Wang XL, Ling TY, Charlesworth MC, et al. Autoimmunoreactive IgGs against cardiac lipid raft-associated proteins in patients with postural orthostatic tachycardia syndrome. Transl Res. 2013;162(1):34–44.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Yu X, Li H, Murphy TA, et al. Angiotensin II type 1 receptor autoantibodies in postural tachycardia syndrome. J Am Heart Assoc. 2018.  https://doi.org/10.1161/jaha.117.008351.Google Scholar
  47. 47.
    Loebel M, Grabowski P, Heidecke H, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun. 2016;52:32–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace. 2017;19(7):1211–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Bagai K, Song Y, Ling JF, et al. Sleep disturbances and diminished quality of life in postural tachycardia syndrome. J Clin Sleep Med. 2011;7:204–10.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Bagai K, Wakwe CI, Malow B, et al. Estimation of sleep disturbances using wrist actigraphy in patients with postural tachycardia syndrome. Auton Neurosci. 2013;177:260–5.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Okamoto LE, Raj SR, Peltier A, et al. Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes. Clin Sci (Lond). 2012;122:183–92.CrossRefPubMedGoogle Scholar
  52. 52.
    Shanks L, Jason LA, Evans M, Brown A. Cognitive impairments associated with CFS and POTS. Front Physiol. 2013;4:113.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Nwazue VC, Paranjape SY, Black BK, et al. Postural tachycardia syndrome and inappropriate sinus tachycardia: role of autonomic modulation and sinus node automaticity. J Am Heart Assoc. 2014;3:e000700.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Fu Q, Verheyden B, Wieling W, Levine BD. Cardiac output and sympathetic vasoconstrictor responses during upright tilt to presyncope in healthy humans. J Physiol. 2012;590:1839–48.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Raj SR, Coffin ST. Medical therapy and physical maneuvers in the treatment of the vasovagal syncope and orthostatic hypotension. Prog Cardiovasc Dis. 2013;55:425–33.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009;20:352–8.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Joyner MJ, Masuki S. POTS versus deconditioning: the same or different? Clin Auto Res. 2008;18(6):300–7.CrossRefGoogle Scholar
  58. 58.
    Freeman R, Lirofonis V, Farquhar WB, Risk M. Limb venous compliance in patients with idiopathic orthostatic intolerance and postural tachycardia. J Appl Physiol. 2002;93:636–44.CrossRefPubMedGoogle Scholar
  59. 59.
    Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects. Circulation. 2002;105(19):2274–81.CrossRefPubMedGoogle Scholar
  60. 60.
    Masuki S, Eisenach JH, Johnson CP, et al. Excessive heart rate response to orthostatic stress in postural tachycardia syndrome is not caused by anxiety. J Appl Physiol. 2007;102:896–903.CrossRefPubMedGoogle Scholar
  61. 61.
    Raj V, Haman KL, Raj SR, et al. Psychiatric profile and attention deficits in postural tachycardia syndrome. J Neurol Neurosurg Psychiatry. 2009;80:339–44.CrossRefPubMedGoogle Scholar
  62. 62.
    Arnold AC, Haman K, Garland EM, et al. Cognitive dysfunction in postural tachycardia syndrome. Clin Sci (Lond). 2015;128:39–45.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Vogel ER, Sandroni P, Low PA. Blood pressure recovery from Valsalva maneuver in patients with autonomic failure. Neurology. 2005;65(10):1533–7.CrossRefPubMedGoogle Scholar
  64. 64.
    George SA, Bivens TB, Howden EJ, et al. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm. 2016;13(4):943–50.CrossRefPubMedGoogle Scholar
  65. 65.
    Raj S, Sheldon R. Management of postural tachycardia syndrome, inappropriate sinus tachycardia and vasovagal syncope. Arrhythm Electrophysiol Rev. 2016;5(2):122–9.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015;13(8):875–91.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Ruzieh M, Dasa O, Pacenta A, Karabin B, Grubb B. Droxidopa in the treatment of postural orthostatic tachycardia syndrome. Am J Ther. 2017;24(2):e157–61.CrossRefPubMedGoogle Scholar
  68. 68.
    Hoeldtke RD, Bryner KD, Hoeldtke ME, Hobbs G. Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. Clin Auto Res. 2006;16(6):390–5.CrossRefGoogle Scholar
  69. 69.
    Kanjwal K, Saeed B. KarabinB, KanjwalY, GrubbBP. Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome. Am J Ther. 2012;19(1):2–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation. 1997;96:575–80.CrossRefPubMedGoogle Scholar
  71. 71.
    Gordon VM, Opfer-Gehrking TL, Novak V, Low PA. Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. Clin Auton Res. 2000;10:29–33.CrossRefPubMedGoogle Scholar
  72. 72.
    Rowe PC, Calkins H, DeBusk K, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA. 2001;285(1):52–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009;120:725–34.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011;58:167–75.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    McDonald C, Frith J, Newton J. Single Centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13(3):427–30.CrossRefPubMedGoogle Scholar
  76. 76.
    Gaffney FA, Lane LB, Pettinger W, Blomqvist CG. Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia. Chest. 1983;83:436–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Raj SR, Black BK, Biaggioni I, Harris PA. RobertsonD. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111:2734–40.CrossRefPubMedGoogle Scholar
  78. 78.
    Kanjwal K, Karabin B, Sheikh M, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011;34:750–5.CrossRefPubMedGoogle Scholar
  79. 79.
    Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349–55.CrossRefPubMedGoogle Scholar
  80. 80.
    Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25.CrossRefPubMedGoogle Scholar
  81. 81.
    Ruzieh M, Batizy L, Dasa O, Oostra C, Grubb B. The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Scand Cardiovasc J. 2017;51(5):243–7.CrossRefPubMedGoogle Scholar
  82. 82.
    Dahan S, Tomljenovic L, Shoenfeld Y. Postural Orthostatic Tachycardia Syndrome (POTS)-A novel member of the autoimmune family. Lupus. 2016;25(4):339–42.CrossRefPubMedGoogle Scholar
  83. 83.
    Wang XL, Chai Q, Charlesworth MC, et al. Autoimmunoreactive IgGs from patients with postural orthostatic tachycardia syndrome. Proteom Clin Appl. 2012;6(11–12):615–25.CrossRefGoogle Scholar
  84. 84.
    Chaigne B, Mouthon L. Mechanisms of action of intravenous immunoglobulin. Transfus Apher Sci. 2017;56(1):45–9.CrossRefPubMedGoogle Scholar
  85. 85.
    Iodice V, Kimpinski K, Vernino S, Sandroni P, Fealey RD, Low PA. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology. 2009;72(23):2002–8.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Liu X, Treister R, Lang M, Oaklander AL. IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord. 2018;11:1756285617744484.  https://doi.org/10.1177/1756285617744484.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Schroeder C, Vernino S, Birkenfeld AL, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. 2005;353(15):1585–90.CrossRefPubMedGoogle Scholar
  88. 88.
    Clark MB, Davis T. A pediatric case of severe pandysautonomia responsive to plasmapheresis. J Child Neurol. 2013;28(12):1716–9.CrossRefPubMedGoogle Scholar
  89. 89.
    Gupta A, Harris S, Vernino S, Naina HV. Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy. Clin Auton Res. 2015;25(4):255–8.CrossRefPubMedGoogle Scholar
  90. 90.
    Fluge Ø, Risa K, Lunde S, et al. B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. an open-label phase ii study with rituximab maintenance treatment. PLoS One. 2015;10(7):e0129898.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Hoad A, Spickett G, Elliott J, Newton J. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. QJM. 2008;101(12):961–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Cardiovascular MedicineUniversity of California San DiegoLa JollaUSA
  2. 2.Division of Rheumatology, Allergy, and ImmunologyUniversity of California San DiegoLa JollaUSA
  3. 3.Department of Cardiology and Internal Medicine, Collegium MedicumNicolaus Copernicus UniversityBydgoszczPoland

Personalised recommendations